



PATENT & TRADEMARK OFFICE FORM 149	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 4369-1-1	SERIAL NO. 10/071,829
	INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT HOWELL et al.	
	FILING DATE February 7, 2002	GROUP ART 1642	

RECEIVED
NOV 06 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS


*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

1	Gatanaga et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients" pp. 8781-8784 (1990)
2	Gatanaga et al., <i>Lymphokine Research</i> , 9(2): 225-229 (1990)
3	Schall et al., <i>Cell</i> , 61: 361-370 (1990)

 9/25/04

*EXAMINER Initial if reference considered whether or not citation is in conformance with MPLP bus. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449
FORM & TRADEMARK SERVICE

JUL 15 2002

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 4369-1-1	SERIAL NO. 10/071,829
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT HOWELL et al.	
		FILING DATE February 7, 2002	GROUP ART 1642 1643

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP
<i>CE</i>	1	4,708,713	11/24/87	Lentz	604	5.02	
	2	6,017,527	12/12/96	Maraskovsky et al.	424	93.71	
	3	6,231,536	5/15/01	Lentz	604	5.04	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
<i>CE</i>	4	0 184 040 B1	11/6/86	EP				
<i>CE</i>	5	WO 91/0996	7/11/91	PCT				
<i>CE</i>	6	02045064	2/15/90	Japan (Abstract)				
<i>CE</i>	7	WO 96/16666	6/6/96	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)


<i>CE</i>	8	Aderka et al., <i>Cancer Research</i> , 51:5602-5607 (1991)
<i>CE</i>	9	Amit et al., <i>Science</i> , 233:747-753 (1986)
<i>CE</i>	10	Elsasser-Beile et al., <i>Tumor Biology</i> , 15:17-24 (1994)
<i>CE</i>	11	Digel et al., <i>J Clin Invest.</i> , 89:1690-1693 (1992)
<i>CE</i>	12	Lentz, <i>J Biol Resp Mod.</i> , 8:511-527 (1989)
<i>CE</i>	13	Lentz, <i>Therapeutic Apheresis</i> , 3:40-49 (1999)
<i>CE</i>	14	Lentz et al., <i>Japanese Journal of Apheresis</i> , 16:107-114 (1997)
<i>CE</i>	15	Kessler, <i>Blood Purification</i> , 11:150-157 (1993)
<i>CE</i>	16	Panka et al., <i>Proc Natl Acad Sci USA</i> , 85:3080-3084 (1988)

RECEIVED

JUL 18 2002

TECH CENTER 1602/2907

CE 9/25/04



FORM PTO-1449 PATENT & TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO 4369-1-1	SERIAL NO 10/071.829
	INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT HOWELL et al.	
		FILING DATE February 7 2002	GROUP ART 1642 /641

17	Rudikoff et al. <i>Proc Natl Acad Sci USA</i> 79 1979-1983 (1982)
18	Selinsky et al. <i>Immunology</i> 94 88-93 (1998)
19	Selinsky and Howell. <i>Cell Immunol.</i> in press (2000)

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED
JUL 18 2002
TECH CENTER 1600/2900

 9/25/04